Company / R&D Expense
Kura Oncology, Inc. R&D Expense History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$251.1M
FY2025
5-year range
$84.7M / $251.1M
FY2021-FY2025
Trend
+47.7%
vs FY2024
Sector context
#72 of 210
Health Care
What the data says
At $251M, Kura Oncology, Inc.'s r&d expense ranks #72 of 210 in the Health Care sector. R&D Expense has increased for 8 consecutive years, from $26M in FY2017 to $251M in FY2025.
Based on SEC 10-K filings.
$251M in FY2025 with a 5-year CAGR of +33.0%.
Improved from $115M to $251M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +39.3%
- 5-Year CAGR
- +33.0%
- 10-Year CAGR
- -
Sector benchmark
#72 of 210 in Health CareTop 34% of 210This company $251.1M Sector average $644.1M
▼
-61.0% below sector average
Key checks
Key Insights
- Kura Oncology, Inc.'s r&d expense has grown for 8 consecutive years.
- 5-year CAGR of +33.0%, indicating consistent growth.
- In FY2025, r&d expense increased 47.7% year-over-year.
- Ranks #72 out of 210 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.83 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $251.1M | +47.7% |
| FY2024 | $170.0M | +47.5% |
| FY2023 | $115.2M | +24.2% |
| FY2022 | $92.8M | +9.6% |
| FY2021 | $84.7M | +40.3% |
| FY2020 | $60.4M | +26.3% |
| FY2019 | $47.8M | +2.2% |
| FY2018 | $46.8M | +77.0% |
| FY2017 | $26.4M | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Mar 28, 2026